Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look: Revolutionizing Treatment in Hematological Malignancies: Clinical Updates on Obe-cel and AUTO8 Therapies from Autolus Therapeutics

Ticker(s): AUTL

Who's the expert?

Institution: Roswell Park

Medical oncologist with a clinical and preclinical focus on hematologic malignancies and cell therapy
Manages 20-40 patients with Acute Lymphoblastic Leukemia (ALL) per year
Very familiar with Autolus Therapeutics' recent presentation at ASH 2023 regarding the FELIX Phase Ib/II study in relapsed/refractory adult B-ALL

Interview Goal

This interview aims to delve into the latest clinical updates presented by Autolus Therapeutics regarding their innovative CAR T cell therapies, obe-cel and AUTO8. The focus will be on understanding the efficacy, safety, and potential impact of these therapies in treating relapsed/refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL), B-cell non-Hodgkin lymphoma (B-NHL), B-cell chronic lymphocytic leukemia (B-CLL), and refractory multiple myeloma.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.